newsfilter
← Earnings
Earnings Releases·

Eikon Therapeutics — Third Quarter 2026 Earnings Summary

  • Reported a net loss of $86.1 million for Q3 2026, an increase from $71.1 million in the prior-year period, while total operating expenses for the nine months rose 6% year-over-year to $271.3 million, driven by a 21% increase in R&D costs.
  • Updated cash runway guidance to fund operations into Q1 2028, supported by a cash, cash equivalents, and marketable securities balance of $461.7 million as of September 30, 2026.
  • Advanced clinical portfolio with EIK1001 dosing the first patient in the registrational TeLuRide-008 Phase 2/3 NSCLC trial and EIK1001 IND submission for EIK1006 in metastatic prostate cancer.
  • Scheduled key milestones including a prespecified interim analysis for TeLuRide-006 melanoma advancement in H1 2027, with additional data expected for EIK1003, EIK1004, and EIK1005 programs throughout 2027.
  • Strengthened leadership with the appointment of Ching-Pin Chang, M.D., Ph.D., as Executive Vice President and Chief Scientific Officer on September 3, 2026.
Company
EIKON THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology